Clinical Trial Update: SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SB-497115, an oral thrombopoietin receptor agonist, versus placebo in adults with refractory immune thrombocytopenic purpura has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura
• Immune Thrombocytopenia

Drugs mentioned

• SB-497115

Snippet

Sponsor: GlaxoSmithKline | Conditions: Purpura, Thrombocytopaenic, Idiopathic | Phase 2 | Status: COMPLETED